Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.68 |
| ▸ | HTR2A | P28223 | 2/20 | 0.65 |
| ▸ | HTR6 | P50406 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14297213 | 0.85 | HTR1D (0.66) | HTR1DADRB2HTR2AHTR6HTR1A | |
| SCHEMBL9400590 | 0.84 | ADRB2 (0.49) | HTR1DADRB2HTR2AHTR6NQO2 | |
| SCHEMBL3323916 | 0.84 | ADRB2 (0.50) | HTR1DADRB2HTR2AHTR6NQO2 | |
| SCHEMBL3348930 | 0.84 | HTR6 (0.66) | HTR1DADRB2HTR2AHTR6HTR1A | |
| SCHEMBL5923660 | 0.83 | ADRB2 (0.64) | HTR1DADRB2HTR2AHTR6HTR1A | |
| SCHEMBL21333400 | 0.83 | HTR1D (0.64) | HTR1DADRB2HTR2AHTR6HTR1A | |
| SCHEMBL379053 | 0.83 | ADRB2 (0.64) | HTR1DADRB2HTR2AHTR6KDM4E | |
| Hydrochloric Acid SCHEMBL7807646 | 0.83 | HTR1D (0.64) | HTR1DADRB2HTR2AHTR6HTR1A | |
| SCHEMBL658829 | 0.83 | HTR1D (0.64) | HTR1DADRB2HTR2AHTR6HTR1A | |
| Hydrochloric Acid SCHEMBL7681619 | 0.82 | ADRB2 (0.62) | HTR1DADRB2HTR2AHTR6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120886-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | claimed |
| EP-2125721-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-12-02 | — | — | EP | claimed |
| WO-2008092666-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-08-07 | — | — | WO | claimed |
| EP-1953141-A1 | Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-06 | — | — | EP | claimed |
| US-20100120886-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| EP-2125721-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008092666-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-08-07 | — | — | WO | disclosed |
| EP-1953141-A1 | Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120886-A1 | ARYL-SUBSTITUTED SULFONAMIDES FOR THE TREATMENT OF COGNITIVE OR FOOD INGESTION RELATED DISORDERS | HTR6, HTR2A, HTR2C | HTR1D 19/4885ADRB2 1596/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.